MD Anderson Cancer Center

A Global Perspective to

Eliminate Cancer

Hilario E. Mata, PhD, MBA

Director, Global Academic Programs

The mission of The University of Texas M. D. Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

We shall be the premier cancer center in the world, based on the excellence of our people, our research-driven patient care and our science. We are Making Cancer History™

#1 Cancer Center in the

U.S.A.

Ranked No. 1 U.S.

cancer hospital for

10 out of 12 years

The Texas Medical Center

MD Anderson Campuses at the

Texas Medical Center

15.3 millions

gross square

feet in operation

North Campus Cores

• Sequencing and Microarray

• Research Animal Support*

• Genetically Engineered Mouse

Facility*

• Small Animal Imaging*

• Tissue Biospecimen and

Pathology Resource*

• Flow Cytometry*

• Patient-Reported Outcomes

• Biostatistics

• Bioinformatics

• Clinical Trials Support

• Clinical and Translational

Research Center

• shRNA and ORFeome

• eHealth

South Campus Cores

• Chemistry

• Research Animal Support*

• Genetically Engineered

Mouse Facility*

• Small Animal Imaging*

• Tissue Biospecimen and

Pathology Resource*

• Characterized Cell Line Core

• Electron Microscopy

• Flow Cytometry*

• Monoclonal Antibody

• Reverse Phase Protein Array

• TALENs

North Campus Facilities

Cancer Prevention Building

Mitchell Basic Science Research Building

Mays Clinic

Alkek Hospital & Lutheran Pavilion

LeMaistre Clinic

Clark Clinic

Pickens Academic Tower

North Campus Aerial View

South Campus Facilities Research Building 3

Research Building 2

Smith Research Building Research Building 3

Research Building 1

MD Anderson Strengths

Largest freestanding cancer center in the world - nearly 30,000 employees, faculty, trainees, & volunteers

Delivers the highest standard of cancer treatment and care - unprecedented breadth and depth of clinical oncology data and knowledge

Tremendous expertise due to the large numbers of cancer patients treated in care centers - 120,000 a year, 1/3rd new patients

Performs the greatest number of cancer clinical trials in the world each investigating new therapies >1,000 trials

Receives the highest level of peer-reviewed National Cancer Institute funding among all US universities - $182M in federal grants/year

An extensive track record of research milestones and setting standards of care for cancer

Resources

TOTAL OPERATING REVENUE FY2013 = $4,135,238,891

$3,178.9 | Net patient revenue | 76.9%

$505.1 | Restricted grants/contracts,

philanthropy | 12.2%

$154.6 | State-appropriated general

revenue | 3.7%

$40.7 | Auxiliary income | 1.0%

$75.6 | Other income | 1.8%

$180.4 | Investment and other non-operating

income | 4.4%

External Funding

Federal Grants & Contracts $182,970,502

Private Industry Grants & Contracts $65,579,036

Philanthropy & Foundation $101,642,898

Total $350,192,436

State & Internal Funding

State-Appropriated General Revenue $11,776,785

Tobacco Settlement Receipts/LEER Funds $5,837,249

CPRIT $24,262,525

Hospital Operating Margins $182,770,342

Institutional Grants $95,730,271

Total $320,377,172

Total Research Expenditures $670,569,608

Research Expenditures FY2013

Clinical Divisions

Radiation Oncology Pathology and Laboratory Medicine Cancer Medicine Pediatrics Cancer Prevention and Population Sciences Quantitative Sciences

Internal Medicine

Surgery

Anesthesiology and Critical

Care

Diagnostic Imaging

Pharmacy

Nursing

Designed to treat specific types of cancer by disease-site that has become MD Anderson’s trademark Built on team approach that bring together surgeons, medical oncologists and radiation oncologists The Method: Research driven patient care, evidence based, performed in a multi-disciplinary setting

Multidisciplinary Care Centers

Multidisciplinary Care Centers

Leukemia

Lymphoma and Myeloma

Melanoma and Skin

Pediatrics

Sarcoma

Stem Cell Transplant

Thoracic

Brain and Spine

Breast

Cancer Prevention

Endocrine

Gastrointestinal

Genitourinary

Head and Neck

Gynecologic

Ambulatory Care Building

Specialty and Treatment Centers

Cancer Prevention

Cardiopulmonary

Integrative Medicine

Internal Medicine

Dermatology

Orthopedic

Pain Management

Proton Treatment

Radiation Treatment

Reconstructive Surgery

Supportive Care

Stem Cell Transplant

and Cellular Therapy

Proton Therapy Center

Survivorship Clinics

Breast

Childhood Cancers

Colorectal

Genitourinary

Gynecologic

Head and Neck

Lymphomas

Melanomas

Stem Cell Transplants

Thyroid

Nutrition, psychosocial, energy balance, side

effects, follow-up medical care, networking

with other survivors

Cancer Prevention Building

Basic Science Departments

Biochemistry and Molecular Biology

Cancer Biology

Genetics

Molecular Carcinogenesis

Immunology

Molecular and Cellular Oncology

Veterinary Medicine and Surgery

Veterinary Sciences

Basic Science Research Building

Institutes

Institute for Applied Cancer Science

Institute for Personalized Cancer Therapy

Institute for Basic Sciences Centers: Biological Pathways, Bio-molecular Structure and Function, Cancer Epigenetics,

Environmental and Molecular Carcinogenesis, Genetics and Genomics, Inflammation and

Cancer, Stem Cell and Developmental Biology

Duncan Family Institute for Cancer Prevention and Risk

Assessment Center for Translational and Public Health Genomics

Institute for Cancer Care Excellence

McCombs Institute for Early Detection and Treatment Centers: Advanced Biomedical Imaging Research, Cancer Immunology, Molecular Markers,

Metastasis, Proton Therapy, RNA Interference and Non-Coding RNA, Targeted Therapy

Institute for Personalized Cancer

Therapy (IPCT)

MD Anderson will be the leader in implementing Personalized Cancer Therapy, based on

an analysis of each patient’s cancer that will integrate information across DNA, RNA,

proteins and metabolomics in the context of the tumor in its microenvironment, the

patient’s immune system and the patient’s own genotype.

Clinical Research Activity 2008-2012

0

2

4

6

8

10

12

14

2008 2009 2010 2011 2012

Patients

Accru

ed (

1000 s

)

Fiscal Year

Interventional Protocols

Industry

Institutional

Ext Peer

National

0

5

10

15

20

25

30

35

2008 2009 2010 2011 2012

Pa

tie

nts

Accru

ed

(1

00

0 s

)

Fiscal Year

Non-interventional Protocols

27,305 27,422 26,348

29,351

o Institutional protocols accounted for >50% of interventional enrollment

o Of 399 industry-sponsored interventional protocols in FY2012, 130

(33%) were authored by or significantly influenced by MD Anderson

investigators

o Non-interventional protocol accruals include bio-specimen collection,

ancillary and correlative studies and observational cohorts

Specialized Programs of Research Excellence (SPORE) Robert Bast P50 CA083639 Ovarian Cancer

Colin Dinney P50 CA091846 Genitourinary Bladder Cancer

Elizabeth Grimm P50 CA093459 Melanoma

Gabriel Hortobagyi P50 CA116199 Breast Cancer

Jean-Pierre Issa P50 CA100632 Leukemia

Scott Lippman P50 CA097007 Head and Neck Cancer

Chris Logothetis P50 CA140388 Prostate Cancer

Karen Lu P50 CA098258 Uterine/Endometrial Cancers

Robert Otlowski P50 CA Myeloma

Jack Roth P50 CA070907 Lung Cancer

Anas Younes P50 CA136411 Lymphoma

Alfred Yung P50 CA127001 rain Cancer

Recent Notable Publications RISK

Hepatocellular Carcinoma Risk Prediction Model for the General Population: The

Predictive Power of Transaminases

Chi-pang Wen…Xifeng Wu, J Natl Cancer Inst 104:1599-1611, 2012

BASIC SCIENCE

ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the

Warburg effect

Weiwei Yang…Zhimin Lu, Nat Cell Biol 14:1295-1304, 2012

TRANSLATIONAL

Oncogenic NRAS signaling differentially regulates survival and proliferation in

melanoma

Lawrence N Kwong…Lynda Chin, Nat Med 18:1503-10, 2012

CLINICAL

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Jorge E. Cortes et al, N Engl J Med 367:2075-88, 2012

SURVIVORSHIP

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

Sui Zhang…Edward T H Yeh, Nat Med 18:1639-42, 2012

Moonshot Program An strategic initiative to apply current knowledge & technology in order to accelerate declines in mortality for several major cancer types within the next 5-10 years. The selected inaugural programs were:

Acute myeloid leukemia / Myelodysplastic syndrome

Chronic lymphocytic leukemia

Melanoma

Lung cancer

Prostate cancer

Triple-negative breast cancer

MD Anderson Global

MDACC

Co-Branded Institutions

Sister Institutions

MD Anderson Madrid - Spain

Opened October 15, 2000

Banner MD Anderson Cancer Center Phoenix

6692 appointments

Scheduled through 1/31/12

688 Initial Consults

684 Infusions

997 Follow-up appointments

916 Radiation treatments

Opened September 26, 2011

GAP Rationale 1. MD Anderson has the determination, values and tools to play a

leading role in eliminating cancer on a global scale

2. We are expanding the reach of our mission by building

relationships with premier academic, health care and

government that share our vision and can help enhance the

international dimension to our academic programs

3. As a leading academic cancer center, it is our obligation to

share our best practices and exchange research and training

with premier cancer programs throughout the world

4. Many key research and epidemiologic questions in cancer can

only be answered with international collaborations

GAP Objectives

1. Expand the availability and improve the quality of cancer care

worldwide by sharing guidelines and pathways while also providing

advice on case management.

2. Broaden the portfolio of basic, clinical and translational research,

which has the potential for advancing diagnostic and therapeutic

services that can provide worldwide benefits.

3. Build significantly on the global talent base of clinicians and

researchers in the field of oncology.

The Sister Institution Network

The GAP team oversees MD Anderson's Sister Institution

relationships and the broader GAP network including

institutions linked to us via memoranda of understanding.

It is the largest such network dedicated to the fight against

cancer in the world, including relationships with over 30

leading regional cancer fighting institutions in 21 countries

throughout North and South America, Asia, Europe,

Australia and Africa.

Sister Institution Network Worldwide

Sister Institutions Affiliations

Australia

1. Peter MacCallum Cancer Centre, Melbourne

Brazil

2. Hospital Israelita Albert Einstein, Sao Paulo

3. Hospital Do Cancer, A. C. Camargo, Sao Paulo

4. Hospital Do Cancer de Barretos

Chile

5. Clinica Alemana, Santiago

Colombia

6. Instituto de Cancerología Las Américas, Medellín

Sister Institutions Affiliations (cont.)

China

7. Fudan University Cancer Hospital, Shanghai

8. Peking Union Medical College Cancer Institute, Beijing

9. Sun Yat-Sen University Cancer Center, Guangzhou

10. Tianjin Medical University Cancer Institute, Tianjin

11. Chinese University of Hong Kong, Hong Kong

France

12. Institut Gustave Roussy, Villejuif

Germany

13. German Cancer Research Center, Heidelberg

Sister Institutions Affiliations (cont.)

India

14. All India Institute of Medical Science, Delhi

15. Tata Memorial Center, Mumbai

Israel

16. Sheba Medical Center, Tel Aviv

Japan

17. Kyoto University Graduate School of Med., Kyoto

18. Tokyo Oncology Consortium, Tokyo

Jordan

19. King Hussein Cancer Center, Amman

Sister Institutions Affiliations (cont.)

Korea

20. Yonsei University Medical Center, Seoul

Lebanon

21. The American University of Beirut, Beirut

Mexico

22. National Cancer Institute, Mexico City

Norway

23. Norwegian Cancer Consortium

Stavanger University Hospital, Stavanger

Norwegian Radium Hospital, Oslo

Cancer Registry of Norway, Oslo

Sister Institutions Affiliations (cont.)

Poland

Polish Cancer Consortium

Sweden

Karolinska Institute, Stockholm

Turkey

Hacettepe University Institute of Oncology, Ankara

Taiwan

China Medical University Hospital, Taichung

United Kingdom

Imperial College of London, London

Signing Ceremony

Academic Activities

Basic, translational and clinical research collaborations

Education exchanges: fellowships, training,

observerships, MD/PhD programs, etc.

Scientific symposia

Medical education by Internet, videoconferencing or

satellite broadcasting

Symposia

Videoconferences

Research Collaborations

Tissue and tumor banking

Immunology

Gene therapy

Bronchial airway research

Microarray research and technology

Traditional Chinese medicine

Endocrinology

Radiation and surgical oncology

Leukemia, breast, thoracic, genitourinary, hepatobiliary colorectal, gastric and head & neck cancers

Sister Institution Network Fund (SINF)

Funding mechanism to continue enhancing collaborations in

research and education within the Sister Institution Network

Eligibility: only projects developed in collaboration between

faculty/staff at MD Anderson and one or more collaborating

institutions are considered for funding

Funding: up to $100,000 over one or two years for MD Anderson

investigators. Funding levels and mechanisms for investigators at

collaborating institutions to be determined by their home institution.

SINF - up to date

• 61 projects

• 3 RFAs (FY11/12/13)

• 36 collaborating

institutions

• 23 countries

• “Collaborate Globally &

Fund locally”

MD Anderson: $6.1M

Network: $6.4M

Total: $12.5M

First Papers Coming Out

• Nature (2); NEJM; Cell; Mol

Cell; Nat Cell Biol; JBC (2)

First Grants

• NCI (4); CPRIT (2); foundation

• 10+ cancer types

• broad range of research

• http://bit.ly/SINF_vis_iPad

Clinical

Basic

GAP Activities – Research (publications)

Collaborative publications co-authored with Sister Institution Faculty Many of the top institutions we co-author with are part of the Sister Institution Network

DKFZ (German Cancer

Research Center) is affiliated

with University of Heidelberg

Data obtained from SciVal Experts - www.mdanderson.org/scival

SINF started

GAP started

GAP Activities: Research (clinical trials)

In 2011 gathered an “inventory” of the capabilities of 17 of our Sister Institutions

regarding clinical trials – shared this internally with clinical investigators

Instituto De Cancerologia, Clinica Las Americas, Medellin, Colombia:

• *Conservative surgery for women with low-risk, early cervical cancer

• *Laparoscopic approach to cervical carcinoma: a phase III randomized clinical trial of laparoscopic or

robotic radical hysterectomy versus abdominal radical hysterectomy in patients with early stage

cervical cancer

Fudan University Cancer Center, Shanghai, China:

• External qigong therapy for women with breast cancer prior to surgery

• Pilot study of Huachansu in patients with hepatocellular carcinoma, small cell lung cancer or pancreatic

cancer (Phase I)

• *Huachansu and gemcitabine in pancreatic cancer (Phase II)

Sheba Medical Center, Tel Hashomer, Israel & University of Heidelberg, Germany:

• A phase I, open-label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of

INNO-406 in adult patients with Imatinib-resistant or intolerant Ph+ leukemias

Institute Gustave Roussy, Paris, France:

• A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI) refractory

differentiated thyroid cancer (DTC)

SciVal Experts

Track your own pu

Track publications and identify experts and publications

Increasing visibility across the research community

Identify potential collaborators and discover new relationships

Find funding opportunities and connect authors to sponsors

A directory of research expertise to find

collaboration within your institution and

the Sister Institution network

Annual GAP Conference

Provides a forum for faculty from MD Anderson and our Sister

Institutions to develop collaborations and exchange research

results and ideas

Sessions are formed around topics of interest to the members of

the SI Network

The event is held at MD Anderson in odd years and is hosted by

a Sister Institution in even years

GAP 2014 Conference, Seoul, Korea

May 1 – 3, 2014 -

Annual GAP Conference

GAP Strategy

Expand the Sister Institution network by creating

regional clusters with similar missions, economic, social

and cultural backgrounds.

Develop programs in line with MD Anderson’s vision,

driven by faculty interest and commitment that benefit all

participants

Encourage and support multi-institutional collaborations,

primarily in clinical research to generate high-impact

breakthroughs which impact cancer care worldwide

The Worldwide Innovative Networking (WIN) Consortium

WIN Consortium in personalized cancer medicine was created

in 2010 by MD Anderson and IGR to accelerate pace and

reduce costs of translating novel cancer treatments through

worldwide clinical trials and research projects

Goal: to make an impact on personalized cancer therapy by

increasing the number of patients having access to innovative,

global clinical trials in the area of genomic-based cancer

therapeutics

Aims: to initiate research projects each year in a global

consortium guided by an independent scientific advisory board

SI Iberoamerican Summit – Nov. 2012

Clinical and translational research

1. Conservative Surgery for Women with Low-Risk, Early

Stage, Cervical Cancer

2. A Phase III Randomized Trial of Laparoscopic or

Robotic Radical Hysterectomy vs. Abdominal Radical

Hysterectomy in Patients with Early Stage Cervical Cancer

Cervical cancer is much prevalent in Colombia

Outstanding contribution by IDC - to date, they remain the center with the highest and fastest accrual in both studies

Prevention / Training & education

3. Integrative Epidemiology Global Training Program

Galvanize on the potential of the SI Network by

recognizing commonalities and identifying opportunities:

Integrative Epidemiology Global Training Program

Preeminent, and sustained training in contemporary &

translational epidemiologic approaches across the lifespan of

cancer care continuum, including:

Integrative Epidemiology

Integrative Prediction Model

Cancer Registry & Population Sciences

Biomarker Discovery

Computational Epidemiology & “omics”

Integrative Risk Models

Global Prevention Initiatives

Nov. 27, 2012 – LOI signed by the Commission of National

Institutes and High Specialty Hospitals of Mexico, the National

Cancer Institute of Mexico and MD Anderson Cancer Center

Oct. 15, 2013 – LOI signed by the Government of the City of

Medellin, the Instituto de Cancerologia Clinica las Americas

and MD Anderson Cancer Center, for:

The development of community-based tobacco use prevention and control pilot

programs for children and adolescents

The development of formalized prevention and control programs , including

programs related to public health policy, education for the public and professionals,

clinical and community services, comprehensive initiatives, research endeavors;

and other public health and academic programs

The implementation, evaluation, refinement and dissemination of prevention and

control programs.

Mexico – Texas Tobacco Control Initiative

Thank You